drugset

drugset / Trial / NCT06104683

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

NCT06104683 ↗

Phase 2 Withdrawn Loxo Oncology, Inc. Eli Lilly and Company · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess efficacy and safety of pirtobrutinib in participants with relapsing multiple sclerosis.

Timeline

Start: 2024-05-01
Primary completion: 2026-01-16
Completion: 2026-02-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pirtobrutinib	Other / unclassified	—	Oral

Indications